SBIR/STTR Research Award
Multi Injection Vial Anti-contamination cap (MIVA-Cap)
Award amount
$167,470Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Defense
- Branch
- Office for Chemical and Biological Defense
- Recipient company
- CHROMOLOGIC LLC
- Proposal award date
- 2022-02-14
- Contract end date
- 2022-08-13
- UEI
- D9EVNTKKWLF3
- Solicitation number
- 21.2
- Topic code
- CBD212-004
Research abstract
To meet CBD’s need for a multi-dose formulation of scopolamine hydrobromide trihydrite ChromoLogic proposes to develop a vial add-on containing a self-decontamination cap with a self-healing material to eliminate evaporation and contamination risks through needle punctures in the septum. CL will also perform forced degradation and stability tests with a panel of preservatives to select optimal preservative/concentration and achieve target shelf-life. Overall, CL plans to work with the CBD to ensure this product is an amendment to their already existing FDA process for approval of their single-dose formulation.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Mitigation of Ionizing Irradiation-Induced Intestinal Damage by Second-Generation Probiotic LR-IFN-β
- Membrane-based AWE Device (MAWED)
- Ceramic membrane based portable oxygen generator (CEMPOG)
- CRISPR-based Assay for Portable Tropical Infection Diagnosis (CAPTIN-D)
- Wearable Heat Related Injury Risk Analysis (WHERA) system Resubmission
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Pharmaceutical Development, Planning, and CMO Identification for the Expedited Advancement of a Scopolamine Multi-Dose-Vial Drug Product
- Stable Antimicrobial Formulation of Scopolamine for Multi-dose Vial
- Formulation and analytical development of a multi-dose vial presentation of scopolamine hydrobromide trihydrate containing a antimicrobial preservatives (AMP)
- Stable Antimicrobial Formulation of Scopolamine for Multi-dose Vial
Research funding history
93 SBIR/STTR records share this UEI (2007–2025). Reported award amounts total $49,103,552. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Defense, Department of Health and Human Services, National Aeronautics and Space Administration, Department of Energy